Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5282)
All Articles published online
|
Aug 15, 2014 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pathophysiology
ISSN
2150-5330
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zampeli E, Gizis M, Siakavellas SI, Bamias G. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(3): 293-303 [PMID: 25133030 DOI: 10.4291/wjgp.v5.i3.293] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5330/full/v5/i3/293.htm |
| Number | Citing Articles |
| 1 |
Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflammatory Bowel Diseases 2023; 29(1): 51 doi: 10.1093/ibd/izac061
|
| 2 |
Haridarshan Patel, Trevor Lissoos, David T. Rubin, Shree Ram Singh. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLOS ONE 2017; 12(4): e0175099 doi: 10.1371/journal.pone.0175099
|
| 3 |
Loris Lopetuso, Viviana Gerardi, Valerio Papa, Franco Scaldaferri, Gian Rapaccini, Antonio Gasbarrini, Alfredo Papa. Can We Predict the Efficacy of Anti-TNF-α Agents?. International Journal of Molecular Sciences 2017; 18(9): 1973 doi: 10.3390/ijms18091973
|
| 4 |
Motohiro Esaki, Yutaro Ihara, Naoyuki Tominaga, Hironobu Takedomi, Nanae Tsuruoka, Takashi Akutagawa, Takahiro Yukimoto, Keisuke Kawasaki, Junji Umeno, Takehiro Torisu, Yasuhisa Sakata. Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn’s disease: tertiary centers experience in Japan. International Journal of Colorectal Disease 2023; 38(1) doi: 10.1007/s00384-023-04359-z
|
| 5 |
Pauline Lemmens, Edouard Louis, Wouter Van Moerkercke, Lieven Pouillon, Michael Somers, Harald Peeters, Stijn Vanden Branden, Julie Busschaert, Filip Baert, Anneline Cremer, Philippe Potvin, Sophie Dewit, Arnaud Colard, Jo Swinnen, Guy Lambrecht, Christophe Claessens, Barbara Willandt, Pieter Dewint, Evi Van Dyck, Joao Sabino, Séverine Vermeire, Marc Ferrante. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study. Clinical Gastroenterology and Hepatology 2024; 22(1): 154 doi: 10.1016/j.cgh.2023.06.023
|
| 6 |
Luiz C Di Stasi, Celso ARA Costa, Aline Witaicenis. Products for the treatment of inflammatory bowel disease: a patent review (2013 – 2014). Expert Opinion on Therapeutic Patents 2015; 25(6): 629 doi: 10.1517/13543776.2015.1041921
|
| 7 |
Yu Nishida, Shuhei Hosomi, Hirokazu Yamagami, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Tetsuya Tanigawa, Masatsugu Shiba, Kenji Watanabe, Toshio Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara, Emiko Mizoguchi. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. PLOS ONE 2017; 12(1): e0169845 doi: 10.1371/journal.pone.0169845
|
| 8 |
Taku Kobayashi, Yasuo Suzuki, Satoshi Motoya, Fumihito Hirai, Haruhiko Ogata, Hiroaki Ito, Noriko Sato, Kunihiko Ozaki, Mamoru Watanabe, Toshifumi Hibi. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. Journal of Gastroenterology 2016; 51(3): 241 doi: 10.1007/s00535-015-1102-z
|
| 9 |
Hu Zhang, Zhen Zeng, Arjudeb Mukherjee, Bo Shen. Molecular diagnosis and classification of inflammatory bowel disease. Expert Review of Molecular Diagnostics 2018; 18(10): 867 doi: 10.1080/14737159.2018.1516549
|
| 10 |
SUSAN D Ghiassian, IVAN VOITALOV, JOHANNA B WITHERS, MARC SANTOLINI, ALIF SALEH, VIATCHESLAV R AKMAEV. Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. Translational Research 2022; 246: 78 doi: 10.1016/j.trsl.2022.03.006
|
| 11 |
Guillaume Pineton de Chambrun, Aurélien Amiot, Guillaume Bouguen, Stéphanie Viennot, Romain Altwegg, Edouard Louis, Michael Collins, Mathurin Fumery, Florian Poullenot, Laura Armengol, Anthony Buisson, Vered Abitbol, David Laharie, Philippe Seksik, Stéphane Nancey, Pierre Blanc, Yoram Bouhnik, Benjamin Pariente, Laurent Peyrin-Biroulet, Maria Nachury, Gilles Boschetti, Bernard Flourié, Pauline Danion, Guillaume Savoye, Franck brazier, Julien Loreau, Laurent Beaugerie, Harry Sokol, I. Nion-Larmurier, A. Bourrier, C. Landman, J. Lefèvre, N. Chafai, Najima Bouta, Natalie Funakoshi. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology 2020; 18(3): 620 doi: 10.1016/j.cgh.2019.05.060
|
| 12 |
Susan D. Ghiassian, Johanna B. Withers, Marc Santolini, Alif Saleh, Viatcheslav R. Akmaev. RETRACTED: Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. Translational Research 2022; 239: 35 doi: 10.1016/j.trsl.2021.04.010
|
| 13 |
Olivier Courbette, Camille Aupiais, Jérôme Viala, Jean‐Pierre Hugot, Xavier Roblin, Sophie Candon, Baptiste Louveau, Lucienne Chatenoud, Christine Martinez‐Vinson. Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology and Nutrition 2020; 70(3): 310 doi: 10.1097/MPG.0000000000002536
|
| 14 |
Liren Li, Xianjing Miao, Runzhou Ni, Xiaobing Miao, Liang Wang, Xiaodan Gu, Lijun Yan, Qiyun Tang, Dongmei Zhang. Epithelial-specific ETS-1 (ESE1/ELF3) regulates apoptosis of intestinal epithelial cells in ulcerative colitis via accelerating NF-κB activation. Immunologic Research 2015; 62(2): 198 doi: 10.1007/s12026-015-8651-3
|
| 15 |
Seok-Young Kim, Seung Yong Shin, Soo Jung Park, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Maham Saeed, Jung Min Moon, Kisung Kim, Chang Hwan Choi, Hyung-Kyoon Choi. Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231168199
|
| 16 |
James O. Lindsay, Alessandro Armuzzi, Javier P. Gisbert, Bernd Bokemeyer, Laurent Peyrin-Biroulet, Geoffrey C. Nguyen, Michael Smyth, Haridarshan Patel. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2017; 49(10): 1086 doi: 10.1016/j.dld.2017.07.010
|
| 17 |
Marco Daperno, Alessandro Armuzzi, Silvio Danese, Walter Fries, Giuseppina Liguori, Ambrogio Orlando, Claudio Papi, Mariabeatrice Principi, Fernando Rizzello, Angelo Viscido, Paolo Gionchetti. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterology Research and Practice 2019; 2019: 1 doi: 10.1155/2019/3108025
|
| 18 |
Jim O’Connell, Cathy Rowan, Roisin Stack, Grace Harkin, Vikrant Parihar, Grace Chan, Niall Breslin, Garret Cullen, Cara Dunne, Laurence Egan, Gavin Harewood, Jan Leyden, Finbar MacCarthy, Padraic MacMathuna, Nasir Mahmud, Susan McKiernan, Deirdre McNamara, Hugh Mulcahy, Frank Murray, Anthony O’Connor, Aoibhlinn O’Toole, Stephen Patchett, Barbara Ryan, Juliette Sheridan, Eoin Slattery, Glen Doherty, David Kevans. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology & Hepatology 2018; 30(9): 1019 doi: 10.1097/MEG.0000000000001177
|
| 19 |
Azade Amini Kadijani, Hamid Asadzadeh Aghdaei, Dario Sorrentino, Alireza Mirzaei, Shabnam Shahrokh, Hedieh Balaii, Vu Q Nguyen, Jessica L Mays, Mohammad Reza Zali. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clinical and Translational Gastroenterology 2017; 8(9): e117 doi: 10.1038/ctg.2017.44
|
| 20 |
Rocío Prieto-Pérez, Berta Almoguera, Teresa Cabaleiro, Hakon Hakonarson, Francisco Abad-Santos. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease. International Journal of Molecular Sciences 2016; 17(2): 225 doi: 10.3390/ijms17020225
|
| 21 |
Natasa Smrekar, David Drobne, Lojze M. Smid, Ivan Ferkolj, Borut Stabuc, Alojz Ihan, Andreja Natasa Kopitar. Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease. Radiology and Oncology 2018; 52(4): 443 doi: 10.2478/raon-2018-0045
|
| 22 |
William J Sandborn, Alessandro Armuzzi, Giuseppina Liguori, Peter M Irving, Ala I Sharara, Rajiv Mundayat, Nervin Lawendy, John C Woolcott, Silvio Danese. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2022; 28(9): 1338 doi: 10.1093/ibd/izab278
|
| 23 |
Maryam Zafer, Hui Zhang, Sujaata Dwadasi, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic. A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohn's & Colitis 360 2022; 4(1) doi: 10.1093/crocol/otab082
|
| 24 |
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
|
| 25 |
Luisa Castro Laria, Federico Argüelles Arias, Valle García Sánchez, José Manuel Benítez, Ramón Fernández Pérez, Ana María Trapero Fernández, Francisco Gallardo Sánchez, Héctor Pallarés Manrique, María Gómez García, María José Cabello Tapia, Aurora Talavera Fabuel, Ana Bejarano García, Eduardo Leo Carnerero, Álvaro Hernández Martínez, Ángel Caunedo Álvarez, Juan Manuel Herrerías-Gutiérrez. Initial experience with golimumab in clinical practice for ulcerative colitis. Revista Española de Enfermedades Digestivas 2016; doi: 10.17235/reed.2016.4068/2015
|
| 26 |
Alessandro Armuzzi, Paolo Gionchetti, Marco Daperno, Silvio Danese, Ambrogio Orlando, Maria Lia Scribano, Maurizio Vecchi, Fernando Rizzello, Sandro Ardizzone, Alessandro Armuzzi, Fabiana Castiglione, Silvio Danese, Marco Daperno, Massimo Fantini, Gionata Fiorino, Giuseppe Frieri, Paolo Gionchetti, Luca Neri, Ambrogio Orlando, Fernando Rizzello, Maria Lia Scribano, Giacomo Carlo Sturniolo, Maurizio Vecchi. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease 2016; 48(4): 360 doi: 10.1016/j.dld.2015.12.016
|
| 27 |
Scott D. Lee, Jessica R. Allegretti, Flavio Steinwurz, Susan B. Connelly, Nervin Lawendy, Jerome Paulissen, Krisztina B. Gecse. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-022-02508-2
|
| 28 |
Hannah Hoseyni, Yan Xu, Honghui Zhou. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?. The Journal of Clinical Pharmacology 2018; 58(7): 864 doi: 10.1002/jcph.1084
|